QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Simulations Plus, Inc. (SLP)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
2

Do Nothing: ATR14 is $0.04 (0.22% of price), below the 1.0% minimum — the stock is deal-pinned beneath the $18.50 Altaris cash offer and too range-compressed to reach an ATR-scaled target — and 20-day average dollar volume ≈ $3.26M is below the $5M liquidity floor.

Analysis as of 2026-09-15· more than 2 trading days ago

Company overview

Simulations Plus, Inc. develops software and services to enhance drug discovery and development, utilizing AI and machine learning for molecular modeling and simulation. Its business units include Simulations Plus, Cognigen, DILIsym, and Lixoft, offering products like GastroPlus and ADMET Predictor. The company serves pharmaceutical, biotechnology, agrochemical, cosmetic, and food industries globally.

Fundamental

fair
Fundamental3
Mixed fundamentals

Strong liquidity and margins are offset by high valuation and merger-related uncertainties.

Score 3/5 (Mixed): Strong liquidity and net-cash balance sheet with healthy trailing margins (gross ~63%, net ~10%), but valuation is rich (P/E ~44, EV/EBITDA ~26) and the announced $18.50/share cash merger largely caps upside while introducing deal-close risk.

Sentiment

fair
Sentiment3
Merger-arb dynamics

Sentiment is neutral, driven by merger-arbitrage conditions with limited upside.

Dominant catalyst is the announced ~$375M all-cash Altaris take-private of SLP at $18.50/share (confidence: announced; HSR cleared 2026-08-13; close expected Q4 2026, date TBD), but the premium is essentially fully reflected with the stock at $18.41 and the sentiment delta is indeterminate (sparse baseline). The current tape is mixed — 13G institutional accumulation (BlackRock, First Light) offset by cautious consensus Reduce/$17.25 sell-side coverage and a tail of law-firm investigation noise; Red-Flag Screen clean, no cap applied.

Technical

weak
Technical2
Deal-pinned range

The stock is range-bound beneath the merger offer, with insufficient volatility for trading.

SLP trades at 18.41, glued to a ~10-cent band (18.36–18.46) for six weeks beneath the $18.50 Altaris cash offer (~0.5% spread) — a classic deal-pinned merger-arb tape. Price sits at the SMA20 (18.41), just above the SMA50 (18.34) and far above the SMA200 (16.39), while the whole short-term MA cluster (EMA9 18.42 / EMA21 18.39 / WMA9 18.42 / WMA21 18.41) is compressed into ~3 cents. RSI14 59.84 and Williams %R −62.5 are neutral; MACD (line 0.04 vs signal 0.06, histogram −0.01) is flat-topped above zero, not expanding; ADX14 39.53 is elevated but direction-agnostic on a pinned tape. ATR14 is $0.04 — 0.22% of price — far below the 1.0% minimum tradable range, so ATR-scaled targets (entry + 2–3.5×ATR = +$0.08–0.14) land at the $18.50 deal cap or above it (18.55), unreachable. 20-day average dollar volume ≈ $3.26M also sits below the $5M liquidity floor. No tradable bullish setup exists: this is merger-arb compression, not a momentum breakout, pullback, oversold reversal, MA crossover or range expansion. Do Nothing.

You’re looking at 2026-09-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.